Institutional Ownership
Enliven Therapeutics Inc
CUSIP 29337E102COMELVNQ1 2026
13D / 13G Filings
41
Schedule 13D/13G on record
Beneficial Filers
14
Distinct reporting persons
Largest Stake
21.8%
Max % of class reported
Institutional Holders
169
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
41 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Vestal Point Capital, LP | 13G | 6.5% | 3.83M | SEC |
| 2 | Nov 14, 2025 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.4% | 3.23M | SEC |
| 3 | Nov 5, 2025 | Fmr LLC | 13G/A | 13.3% | 7.87M | SEC |
| 4 | Aug 14, 2025 | Commodore Capital LP | 13G/A | 11.0% | 6.02M | SEC |
| 5 | Aug 14, 2025 | Polar Capital Holdings PLC | 13G | 5.2% | 2.54M | SEC |
| 6 | Aug 14, 2025 | Fairmount Funds Management LLC | 13G/A | 11.0% | 3.71M | SEC |
| 7 | Jul 17, 2025 | Blackrock, Inc. | 13G/A | 5.1% | 2.94M | SEC |
| 8 | Jun 17, 2025 | Orbimed Advisors LLC | 13D/A | 13.4% | — | SEC |
| 9 | Feb 14, 2025 | Polar Capital Holdings PLC | 13G/A | 4.9% | 2.39M | SEC |
| 10 | Feb 14, 2025 | Fairmount Funds Management LLC | 13G/A | 11.0% | 3.20M | SEC |
31 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Enliven Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Orbimed Advisors LLC | 7.96M | $312.01M |
| 2 | Fmr LLC | 6.83M | $267.71M |
| 3 | Polar Capital Holdings PLC | 5.07M | $198.58M |
| 4 | Blackrock, Inc. | 3.68M | $144.44M |
| 5 | Commodore Capital LP | 3.27M | $128.38M |
| 6 | Vestal Point Capital, LP | 3.25M | $127.40M |
| 7 | Bellevue Group AG | 2.32M | $90.98M |
| 8 | Vanguard Capital Management LLC | 2.17M | $84.99M |
| 9 | Fairmount Funds Management LLC | 1.86M | $72.74M |
| 10 | Citadel Advisors LLC | 1.74M | $68.36M |